FIGURE 1.
Workflow for preclinical evaluation of 125I-KX1 in high-risk neuroblastoma. Nineteen human neuroblastoma cell lines were screened for cytotoxic sensitivity to 125I-KX1. IMR-05 and NLF were chosen as representative cell lines for downstream experiments. Radioligand binding assay, immunofluorescence microscopy, and further cytotoxicity screening were followed by in vitro and in vivo radiation dosimetry.